Spero Therapeutics recently received a grant from the National Institue of Health (NIH) to conduct preclinical studies of SPR720, the company's novel oral bacterial gyrase inhibitor, for the treatment of tuberculosis (TB).
Spero will collaborate with the Central New York Research Corporation (name changed to Veterans Health Research Institute of Central New York , Inc. in 2020) to assess the safety and efficacy of SPR720 in combination with rifampin and other existing standard-of-care drugs in preclinical models of both drug-susceptible TB and multidrug-resistant (MDR) TB.
